Literature DB >> 28586243

Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy.

Kerri M Winters-Stone1, Fay Horak1, Peter G Jacobs1, Phoebe Trubowitz1, Nathan F Dieckmann1, Sydnee Stoyles1, Sara Faithfull1.   

Abstract

Purpose Chemotherapy-induced peripheral neuropathy (CIPN) may persist after treatment ends and may lead to functional decline and falls. This study compared objective and self-report measures of physical function, gait patterns, and falls between women cancer survivors with and without symptoms of CIPN to identify targets for functional rehabilitation. Methods A secondary data analysis of 512 women cancer survivors (age, 62 ± 6 years; time since diagnosis, 5.8 ± 4.1 years) categorized and compared women self-reporting symptoms of CIPN (CIPN+) with asymptomatic women (CIPN-) on the following: maximal leg strength, timed chair stand, physical function battery, gait characteristics (speed; step number, rate, and length; base of support), self-report physical function and disability, and falls in the past year. Results After an average of 6 years after treatment, 47% of women still reported symptoms of CIPN. CIPN+ had significantly worse self-report and objectively measured function than did CIPN-, with the exception of maximal leg strength and base of support during a usual walk. Gait was slower among CIPN+, with those women taking significantly more, but slower and shorter, steps than did CIPN- (all P < .05). CIPN+ reported significantly more disability and 1.8 times the risk of falls compared with CIPN- ( P < .0001). Increasing symptom severity was linearly associated with worsening function, increasing disability, and higher fall risk (all P < .05). Conclusion This work makes a significant contribution toward understanding the functional impact of CIPN symptoms on cancer survivors. Remarkably, 47% of women in our sample had CIPN symptoms many years after treatment, together with worse function, greater disability, and more falls. CIPN must be assessed earlier in the clinical pathway, and strategies to limit symptom progression and to improve function must be included in clinical and survivorship care plans.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28586243      PMCID: PMC5549452          DOI: 10.1200/JCO.2016.71.3552

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  47 in total

1.  Lower extremity performance in nondisabled older persons as a predictor of subsequent hospitalization.

Authors:  B W Penninx; L Ferrucci; S G Leveille; T Rantanen; M Pahor; J M Guralnik
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-11       Impact factor: 6.053

2.  Late Life Function and Disability Instrument: II. Development and evaluation of the function component.

Authors:  Stephen M Haley; Alan M Jette; Wendy J Coster; Jill T Kooyoomjian; Suzette Levenson; Tim Heeren; Jacqueline Ashba
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-04       Impact factor: 6.053

Review 3.  Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.

Authors:  Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse
Journal:  Support Care Cancer       Date:  2014-05-01       Impact factor: 3.603

4.  Falls in persons with chemotherapy-induced peripheral neuropathy.

Authors:  Cindy Tofthagen; Janine Overcash; Kevin Kip
Journal:  Support Care Cancer       Date:  2011-03-05       Impact factor: 3.603

5.  Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study.

Authors:  J S Gewandter; L Fan; A Magnuson; K Mustian; L Peppone; C Heckler; J Hopkins; M Tejani; G R Morrow; S G Mohile
Journal:  Support Care Cancer       Date:  2013-02-28       Impact factor: 3.603

6.  The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.

Authors:  Noah A Kolb; A Gordon Smith; J Robinson Singleton; Susan L Beck; Gregory J Stoddard; Summer Brown; Kathi Mooney
Journal:  JAMA Neurol       Date:  2016-07-01       Impact factor: 18.302

Review 7.  Interventions for preventing falls in older people living in the community.

Authors:  Lesley D Gillespie; M Clare Robertson; William J Gillespie; Sarah E Lamb; Simon Gates; Robert G Cumming; Brian H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

8.  Implementing an evidence-based fall prevention program in an outpatient clinical setting.

Authors:  Fuzhong Li; Peter Harmer; Ronald Stock; Kathleen Fitzgerald; Judy Stevens; Michele Gladieux; Li-Shan Chou; Kenji Carp; Jan Voit
Journal:  J Am Geriatr Soc       Date:  2013-10-28       Impact factor: 5.562

Review 9.  Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research.

Authors:  Cindy Tofthagen; Constance Visovsky; Donna L Berry
Journal:  Oncol Nurs Forum       Date:  2012-09       Impact factor: 2.172

10.  Clinical factors associated with a conservative gait pattern in older male veterans with diabetes.

Authors:  James S Wrobel; Ryan T Crews; John E Connolly
Journal:  J Foot Ankle Res       Date:  2009-04-23       Impact factor: 2.303

View more
  81 in total

1.  Axon Degeneration and Inflammation in Neuropathy: The Role of Acupuncture.

Authors:  Weidong Lu
Journal:  Med Acupunct       Date:  2020-12-16

Review 2.  The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Cindy S Tofthagen; Andrea L Cheville; Charles L Loprinzi
Journal:  Curr Oncol Rep       Date:  2020-04-22       Impact factor: 5.075

3.  Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group.

Authors:  Tanya M Wildes; Ronald J Maggiore; William P Tew; David Smith; Can-Lan Sun; Harvey Cohen; Supriya G Mohile; Ajeet Gajra; Heidi D Klepin; Cynthia Owusu; Cary P Gross; Hyman Muss; Andrew Chapman; Stuart M Lichtman; Vani Katheria; Arti Hurria
Journal:  Support Care Cancer       Date:  2018-04-28       Impact factor: 3.603

4.  Comparison between quantitative and subjective assessments of chemotherapy-induced peripheral neuropathy in cancer patients: A prospective cohort study.

Authors:  Takashi Saito; Daisuke Makiura; Junichiro Inoue; Hisayo Doi; Kimikazu Yakushijin; Atsuo Okamura; Hiroshi Matsuoka; Toru Mukohara; Ryuichi Saura; Yoshitada Sakai; Rei Ono
Journal:  Phys Ther Res       Date:  2020-07-22

5.  Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.

Authors:  J Matt McCrary; David Goldstein; David Wyld; Robert Henderson; Craig R Lewis; Susanna B Park
Journal:  J Cancer Surviv       Date:  2019-06-06       Impact factor: 4.442

6.  Postural sway, falls, and self-reported neuropathy in aging female cancer survivors.

Authors:  Peter C Fino; Fay B Horak; Mahmoud El-Gohary; Carolyn Guidarelli; Mary E Medysky; Sarah J Nagle; Kerri M Winters-Stone
Journal:  Gait Posture       Date:  2019-01-17       Impact factor: 2.840

Review 7.  Risk Factors for Falls in Adult Cancer Survivors: An Integrative Review.

Authors:  Grace Campbell; Rachel A Wolfe; Mary Lou Klem
Journal:  Rehabil Nurs       Date:  2018 Jul/Aug       Impact factor: 1.625

8.  Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy.

Authors:  Paul Lennart Vollmers; Christoph Mundhenke; Nicolai Maass; Dirk Bauerschlag; Stefan Kratzenstein; Christoph Röcken; Thorsten Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-25       Impact factor: 4.553

9.  Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.

Authors:  Weidong Lu; Anita Giobbie-Hurder; Rachel A Freedman; Im Hee Shin; Nancy U Lin; Ann H Partridge; David S Rosenthal; Jennifer A Ligibel
Journal:  Oncologist       Date:  2019-10-14

10.  Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity.

Authors:  Andreas A Argyriou; Jordi Bruna; Garifallia G Anastopoulou; Roser Velasco; Pantelis Litsardopoulos; Haralabos P Kalofonos
Journal:  Support Care Cancer       Date:  2019-08-05       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.